logo-loader

Imugene seeks to activate immune system of cancer patients to identify and eradicate tumours

Last updated: 20:53 10 Mar 2024 EDT, First published: 01:58 22 Jul 2022 EDT

Snapshot

  • Imugene advances to combination dosing with Phase 1 onCARlytics solid tumour trial
  • Imugene progresses onCARlytics solid tumour trial to combination arm
Imugene Ltd

About the company

Imugene Ltd (ASX:IMU) (OTCMKTS:IUGNF) is a clinical-stage immuno-oncology company developing a range of new and novel immunotherapies that seek to activate the immune system of cancer patients to treat and eradicate tumours.

The company's unique platform technologies seek to harness the body’s immune system against tumours, potentially achieving a similar or greater effect than synthetically manufactured monoclonal antibody and other immunotherapies.

Imugene’s product pipeline includes multiple immunotherapy B-cell vaccine candidates and an oncolytic virotherapy (CF33) aimed at treating a variety of cancers in combination with standard of care drugs and emerging immunotherapies such as CAR T’s for solid tumours.

How it is doing

10 Mar 2024

Imugene Ltd (ASX:IMU, OTC:IUGNF) is ready to begin combination dosing solid tumour patients with CD19 targeting drug blinatumomab as part of a Phase 1 clinical trial of CD19 oncolytic virotherapy drug candidate onCARlytics (on-CAR-19, CF33-CD19 HOV4).

The combination arm of the study treatment will see onCARlytics combined with CD19 targeting bispecific monoclonal antibody blinatumomab (marketed as Blincyto® by Amgen which currently is specifically approved only for liquid blood cancers).

Progression to this phase follows onCARlytics clearing its first cohort within the intratumoural monotherapy arm of the study.

Known as OASIS, the first-in-class clinical trial is targeting adult patients with advanced or metastatic solid tumours and aims to evaluate the safety and efficacy of two routes of administration, intratumoural (IT) injection and intravenous (IV) infusion, either alone, or in combination with blinatumomab.

14 Feb 2024

Imugene Ltd (ASX:IMU, OTC:IUGNF) has dosed the first patient with bile tract cancer in the intravenous monotherapy arm of the Phase 1 onCARlytics clinical trial at City of Hope in California, USA. 

Known as the OASIS trial, this is the first-in-class clinical trial targeting adult patients with advanced or metastatic solid tumours — a world-first in combining a CD19-expressing oncolytic virus with a CD19 targeting drug.

18 Jan 2024

Imugene Ltd (ASX:IMU, OTC:IUGNF) has presented a poster on its lead candidate, oncolytic virus CF33-hNIS (VAXINIA), at the ASCO Gastrointestinal (ASCO-GI) Cancers Symposium currently being conducted in San Francisco.

The poster "Oncolytic Virus CF33-hNIS Monotherapy for the Treatment of Gastrointestinal Malignancies" was presented on 18 January 2024 during Session A: Cancers of the Esophagus and Stomach and Other GI Cancers.

What management says

10 Mar 2024

Imugene Ltd (ASX:IMU, OTC:IUGNF) CEO Leslie Chong joins Proactive’s Jonathan Jackson in the Proactive studio to discuss how the company has advanced its Phase 1 onCARlytics solid tumour trial to combination arm treatment. The trial, known as OASIS, focuses on adult patients with advanced or metastatic solid tumours, aiming to assess the safety and efficacy of intratumoural (IT) injection and intravenous (IV) infusion, alone or combined with the CD19 targeting drug blinatumomab (Blincyto® by Amgen). The Cohort Review Committee (CRC) has reported no safety issues in the onCARlytics monotherapy lead-in study, prompting the clearance of the first cohort and the initiation of the combination arm. The OASIS trial represents a pioneering approach in solid tumour treatment, combining a CD19-expressing oncolytic virus to prime tumours for attack by CD19-targeting therapeutics. The trial's potential to shift the paradigm in solid tumour treatment is underlined by the promising advancements, with the combination arm set to explore the efficacy of onCARlytics in conjunction with blinatumomab. Imugene's progress in the OASIS trial signals a significant step forward in advancing novel immunotherapies for solid tumour patients.

Imugene progresses onCARlytics solid tumour trial to combination arm

Imugene Ltd (ASX:IMU, OTC:IUGNF) CEO Leslie Chong joins Proactive’s Jonathan Jackson in the Proactive studio to discuss how the company has advanced its Phase 1 onCARlytics solid tumour trial to combination arm treatment. The trial, known as OASIS, focuses on adult patients with advanced or...

1 week, 2 days ago